- Achieves second quarter revenue growth of 6% as reported and
7% organic, supported by CAG Diagnostics recurring revenue
growth of 6% as reported and 7% organic.
- Solid growth supported by continued benefits from IDEXX
execution drivers, including record second quarter premium
instrument placements and double-digit year-over-year global
premium instrument installed base growth.
- Delivers EPS of $2.44, a decline of 9% as reported
reflecting a $62 million, $0.56 per share discrete expense accrual
related to an ongoing litigation matter. On a comparable basis,
excluding this impact, EPS increased 15%.
- Updates 2024 revenue guidance to $3,885 million - $3,945
million, reflecting 6.2% - 7.8% growth as reported and 6.2% - 7.8%
organic, driven by projected CAG Diagnostics recurring revenue
growth of 5.7% - 7.3% as reported and 6.2% - 7.8% organic.
- Adjusts 2024 EPS outlook to $10.31 - $10.59, a reduction of
$0.56 per share at midpoint reflecting impacts from the $0.56 per
share discrete litigation expense accrual and consistent
expectations for solid comparable operating margin
improvement.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet
healthcare innovation, today announced second quarter results.
Second Quarter Results
The Company reports revenues of $1,004 million for the second
quarter of 2024, an increase of 6% as reported and 7% organic,
driven by Companion Animal Group ("CAG") growth of 6% as reported
and 7% organic, and Water revenue growth of 9% as reported and 10%
organic. CAG Diagnostics recurring revenue growth of 6% as reported
and 7% organic was supported by strong growth in international
regions and sustained global benefits from IDEXX execution drivers.
IDEXX veterinary software, services and diagnostic imaging systems
revenue increased 12% as reported and 8% organic, reflecting high
recurring revenue growth and continued momentum in cloud-based
software placements. Strong interest in IDEXX solutions supported
record second quarter premium instrument placements and 11% annual
growth in IDEXX's global premium instrument installed base.
Second quarter earnings per diluted share (“EPS”) were $2.44, a
decrease of 9% as reported and an increase of 15% on a comparable
basis excluding a $0.56 per share impact related to a discrete
expense accrual for an ongoing litigation matter.
"Continued high levels of execution from IDEXX teams drove solid
global growth and strong operational performance in the second
quarter,” said Jay Mazelsky, President and Chief Executive Officer.
“These results reflect the benefits that IDEXX customers gain from
adopting our innovative, multi-modality testing platforms and
solutions. Veterinarians appreciate the deep diagnostics insights
generated by IDEXX solutions, which help them deliver better
patient outcomes and seamless workflow for better business results.
This value-added partnership, supported by IDEXX innovation, sets a
strong foundation for long-term growth through higher standards of
pet healthcare."
Second Quarter Performance Highlights
Companion Animal Group
The Companion Animal Group generated revenue growth of 6% as
reported and 7% organic for the quarter. Solid growth was supported
by CAG Diagnostics recurring revenue growth of 6% as reported and
7% organic. CAG Diagnostics recurring revenue growth was supported
by 8% reported and 10% organic gains in international regions. U.S.
CAG Diagnostics recurring revenue growth of 5% as reported and
organic remained solidly above sector growth levels in the second
quarter.
Additional U.S. companion animal practice key metrics are
available in the Q2 2024 Earnings Snapshot accessible on the IDEXX
website, www.idexx.com/investors.
Solid global growth was achieved across IDEXX's testing
modalities.
- IDEXX VetLab® consumables generated 7% reported and 8%
organic revenue growth, with solid gains in the U.S. and continued
double-digit organic gains internationally supported by strong
installed base growth across premium instrument platforms.
- Reference laboratory diagnostic and consulting services
generated 5% reported and 6% organic revenue growth, driven by
solid U.S. gains and high single-digit organic growth in
international regions.
- Rapid assay products revenues grew 6% as reported and
organic, driven by solid gains in the U.S., supported by benefits
from higher net price realization.
Veterinary software, services and diagnostic imaging systems
revenues grew 12% as reported and 8% organically, driven by
continued high levels of organic growth in software and diagnostic
imaging recurring revenues and benefits from a recent software and
data platform acquisition.
Water
Water revenues grew 9% as reported and 10% organic for the
quarter, reflecting strong growth in the U.S. and Europe.
Livestock, Poultry and Dairy (“LPD”)
LPD revenues grew 1% as reported and 3% organically for the
quarter. Solid gains in the U.S. and Europe were partially offset
by lower Asia Pacific revenues, including impacts from reduced
swine testing and herd health screening levels.
Gross Profit and Operating Profit
Gross profits increased 8% as reported and 9% on a comparable
basis. Gross margin of 61.7% increased 100 basis points as reported
and 90 basis points on a comparable basis, supported by benefits
from net price realization offsetting inflationary cost impacts,
software service margin gains and favorable business mix.
Operating margin was 26.3% for the quarter, lower than the prior
year by 510 basis points including ~610 basis point negative impact
from $62 million of expense related to a discrete litigation
expense accrual. On a comparable basis excluding this item and
foreign exchange effects, operating margins increased 110 basis
points. Operating margin results reflect 28% operating expense
growth as reported and 7% on a comparable basis excluding expense
related to the discrete litigation accrual.
2024 Growth and Financial Performance Outlook
The Company is updating its full year revenue growth guidance
range to $3,885 million to $3,945 million, or reported growth of
6.2% - 7.8%, a reduction of $15 million at midpoint. This reflects
an adjustment of ~1% at midpoint to full year estimates for organic
revenue growth, which is now projected at 6.2% to 7.8%, reflecting
recent trends in U.S. clinical visit levels. The updated guidance
range includes ~$15 million of favorable impact from more recent
foreign exchange estimates.
The Company updated its full year reported operating margin
outlook to reflect consistent midpoint goals for comparable
operating margin improvement and to incorporate the expenses
related to an ongoing litigation matter. The Company's reported
operating margin outlook is 28.7% - 29.0%, including ~160 basis
points of impact related to the discrete litigation expense
accrual. At midpoint, projected full year comparable operating
profit margin expansion of 30 - 60 basis points includes a ~40
basis point negative growth impact from lapping a customer contract
resolution payment in the first quarter of 2023.
The Company updated its EPS outlook range to $10.31 - $10.59, a
reduction of $0.56 at midpoint, reflecting a $0.56 negative impact
from a discrete litigation expense accrual. Adjustments to the
organic revenue outlook were offset by $0.04 in favorable
adjustments to foreign exchange estimates and favorable refinements
to interest expense and effective tax rate estimates. The updated
EPS growth outlook is 2% - 5% as reported and 9% - 12% on
comparable basis, including a ~2% negative growth impact from
lapping a customer contract resolution payment in the first quarter
of 2023.
The following table provides the Company's updated outlook for
annual key financial metrics in 2024 with a comparison to the prior
outlook:
Amounts in millions except per share data and percentages
2024 Growth and Financial Performance
Outlook
Updated
Prior
Revenue
$3,885
-
$3,945
$3,895
-
$3,965
Reported growth
6.2%
-
7.8%
6.5%
-
8.5%
Organic growth
6.2%
-
7.8%
7.0%
-
9.0%
CAG Diagnostics Recurring Revenue
Growth
Reported growth
5.7%
-
7.3%
6.5%
-
8.5%
Organic growth
6.2%
-
7.8%
7.5%
-
9.5%
Operating Margin
28.7%
-
29.0%
30.2%
-
30.7%
Operating margin expansion
(130 bps)
-
(100 bps)
20 bps
-
70 bps
Negative impact of ongoing litigation
matter
~160 bps
Comparable margin expansion
30 bps
-
60 bps
20 bps
-
70 bps
Negative impact of 2023 customer contract
resolution payment
~ 40 bps
~ 40 bps
EPS
$10.31
-
$10.59
$10.82
-
$11.20
Reported growth
2%
-
5%
8%
-
11%
Negative impact of ongoing litigation
matter
~ 6%
Comparable growth
9%
-
12%
9%
-
13%
Negative impact of 2023 customer contract
resolution payment
~ 2%
~ 2%
Other Key Metrics
Net interest expense
~ $20
~ $21
Share-based compensation tax benefit
~ $10
~ $10
Share-based compensation tax rate
benefit
~ 1%
~ 1%
Effective tax rate
~ 21.5%
~ 22%
Share-based compensation EPS impact
~ $0.12
~ $0.12
Reduction in average shares
outstanding
0.5%
-
1%
0.5%
-
1%
Operating Cash Flow (% of Net
Income)
110% - 115%
110% - 115%
Free Cash Flow (% of Net
Income)
90% - 95%
90% - 95%
Capital Expenditures
~ $180 million
~ $180 million
The following table outlines estimates of foreign currency
exchange rate impacts, net of foreign currency hedging
transactions, and foreign currency exchange rate assumptions
reflected in the above financial performance outlook for 2024.
Estimated Foreign Currency Exchange
Rate Impacts
2024
Revenue growth rate impact
(~ 50 bps)
CAG Diagnostics recurring revenue growth
rate impact
(~ 50 bps)
Operating margin growth impact
~ 0 bps
EPS impact
(~ $0.05)
EPS growth impact
(~ 1%)
Go-Forward Foreign Currency Exchange
Rate Assumptions
2024
In U.S. dollars
euro
$1.07
British pound
$1.26
Canadian dollar
$0.72
Australian dollar
$0.66
Relative to the U.S. dollar
Japanese yen
¥163
Chinese renminbi
¥7.38
Brazilian real
R$5.55
Conference Call and Webcast Information
IDEXX Laboratories, Inc. will be hosting a conference call today
at 9:00 a.m. (EDT) to discuss its second quarter 2024 results and
management’s outlook. To participate in the conference call, dial
1-800-289-0459 or 1-773-305-6837 and reference passcode 399723.
Individuals can access a live webcast of the conference call
through a link on the IDEXX website, www.idexx.com/investors. An
archived edition of the webcast will be available after 1:00 p.m.
(EDT) on that day via the same link and will remain available for
one year.
2024 Investor Day
IDEXX Laboratories, Inc. will host its 2024 Investor Day on
Thursday, August 15, 2024 from 8:00 am to approximately 12:00 pm
(EDT). A live audio webcast and accompanying slide presentations
will be available at www.idexx.com/investors. An archived webcast
replay of the event will be available approximately one hour
following the event at www.idexx.com/investors. For additional
information contact investorrelations@idexx.com.
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare innovation. Our
diagnostic and software products and services create clarity in the
complex, constantly evolving world of veterinary medicine. We
support longer, fuller lives for pets by delivering insights and
solutions that help the veterinary community around the world make
confident decisions—to advance medical care, improve efficiency,
and build thriving practices. Our innovations also help ensure the
safety of milk and water across the world and maintain the health
and well-being of people and livestock. IDEXX Laboratories, Inc. is
a member of the S&P 500® Index. Headquartered in Maine, IDEXX
employs approximately 11,000 people and offers solutions and
products to customers in more than 175 countries and territories.
For more information about IDEXX, visit www.idexx.com.
Note Regarding Forward-Looking Statements
This earnings release and the statements to be made in the
accompanying earnings conference call contain forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, including statements about the Company’s business
prospects and estimates of the Company’s financial results for
future periods. Forward-looking statements are included above under
"2024 Growth and Financial Performance Outlook" and elsewhere and
can be identified by the use of words such as "expects", "may",
"anticipates", "intends", "would", "will", "plans", "believes",
"estimates", "projected", "should", and similar words and
expressions. Our forward-looking statements include statements
relating to our expectations regarding financial performance;
revenue growth and EPS outlooks; operating and free cash flow
forecast; projected impact of foreign currency exchange rates and
interest rates; projected operating margins and expenses and
capital expenditures; projected tax, tax rate and EPS benefits from
share-based compensation arrangements; projected effective tax
rates, reduction of average shares outstanding and net interest
expense; U.S. clinical visit trends; net price realization
improvement; product launches; and the ongoing litigation matter.
These statements are intended to provide management's expectation
of future events as of the date of this earnings release; are based
on management's estimates, projections, beliefs, and assumptions as
of the date of this earnings release; and are not guarantees of
future performance. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the Company's
actual results, levels of activity, performance or achievements to
be materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include,
among other things, the matters described under the headings
"Business," "Risk Factors," "Legal Proceedings," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and "Quantitative and Qualitative Disclosures About
Market Risk" in the Company’s Annual Report on Form 10-K for the
year ended December 31, 2023 and in the corresponding sections of
the Company's Quarterly Reports on Form 10-Q for the quarter ended
March 31, 2024 and June 30, 2024, as well as those described from
time to time in the Company’s other filings with the U.S.
Securities and Exchange Commission available at www.sec.gov. The
Company specifically disclaims any obligation to publicly update
any forward-looking statement, whether as a result of new
information, future events or otherwise.
Statement Regarding Non-GAAP Financial Measures
The following defines terms and conventions and provides
reconciliations regarding certain measures used in this earnings
release and/or the accompanying earnings conference call that are
not required by, or presented in accordance with, generally
accepted accounting principles in the United States of America
("GAAP"), otherwise referred to as non-GAAP financial measures. To
supplement the Company’s consolidated results presented in
accordance with GAAP, the Company has disclosed non-GAAP financial
measures that exclude or adjust certain items. Management believes
these non-GAAP financial measures provide useful supplemental
information for its and investors’ evaluation of the Company’s
business performance and liquidity and are useful for
period-over-period comparisons of the performance of the Company’s
business and its liquidity and to the performance and liquidity of
our peers. While management believes that these non-GAAP financial
measures are useful in evaluating the Company’s business, this
information should be considered as supplemental in nature and
should not be considered in isolation or as a substitute for the
related financial information prepared in accordance with GAAP. In
addition, these non-GAAP financial measures may not be the same as
similarly titled measures reported by other companies.
Constant currency - Constant
currency references are non-GAAP financial measures which exclude
the impact of changes in foreign currency exchange rates and are
consistent with how management evaluates our performance and
comparisons with prior and future periods. We estimated the net
impacts of currency on our revenue, gross profit, operating profit,
and EPS results by restating results to the average exchange rates
or exchange rate assumptions for the comparative period, which
includes adjusting for the estimated impacts of foreign currency
hedging transactions and certain impacts on our effective tax
rates. These estimated currency changes impacted second quarter
2024 results as follows: decreased gross profit growth by 0.7%,
increased gross margin growth by 10 basis points, decreased
operating expense growth by 0.4%, decreased operating profit growth
by 0.9%, decreased operating profit margin growth by 10 basis
points, and decreased EPS growth by 0.7%. Constant currency revenue
growth represents the percentage change in revenue during the
applicable period, as compared to the prior year period, excluding
the impact of changes in foreign currency exchange rates. See the
supplementary analysis of results below for revenue percentage
change from currency for the three and six months ended June 30,
2024 and refer to the 2024 Growth and Financial Performance Outlook
section of this earnings release for estimated foreign currency
exchange rate impacts on 2024 projections and estimates.
Growth and organic revenue growth -
All references to growth and organic growth refer to growth
compared to the equivalent prior year period unless specifically
noted. Organic revenue growth is a non-GAAP financial measure that
represents the percent change in revenue, as compared to the same
period for the prior year, net of the impact of changes in foreign
currency exchange rates, certain business acquisitions, and
divestitures. Management believes that reporting organic revenue
growth provides useful information to investors by facilitating
easier comparisons of our revenue performance with prior and future
periods and to the performance of our peers. Organic revenue growth
should be considered in addition to, and not as a replacement of or
a superior measure to, revenue growth reported in accordance with
GAAP. See the supplementary analysis of results below for a
reconciliation of reported revenue growth to organic revenue growth
for the three and six months ended June 30, 2024. Please refer to
the constant currency note above for a summary of foreign currency
exchange rate impacts. Please refer to the 2024 Growth and
Financial Performance Outlook section of this earnings release for
estimated full year 2024 organic revenue growth for the Company and
CAG Diagnostics recurring revenue growth. The percentage change in
revenue resulting from acquisitions represents revenues during the
current year period, limited to the initial 12 months from the date
of the acquisition, that are directly attributable to business
acquisitions. Revenue from acquisitions is not expected to have
benefit projected full year 2024 revenue growth by 0.5% and have no
impact on CAG Diagnostics recurring revenue growth.
Comparable growth metrics -
Comparable gross profit growth, comparable gross margin gain (or
growth), comparable operating expense growth, comparable operating
profit growth and comparable operating margin gain (or growth) are
non-GAAP financial measures and exclude the impact of changes in
foreign currency exchange rates and non-recurring or unusual items
(if any). Please refer to the constant currency note above for a
summary of foreign currency exchange rate impacts. Management
believes that reporting comparable gross profit growth, comparable
gross margin gain (or growth), comparable operating expense growth,
comparable operating profit growth and comparable operating margin
gain (or growth) provides useful information to investors because
it enables better period-over-period comparisons of the fundamental
financial results by excluding items that vary independent of
performance and provides greater transparency to investors
regarding key metrics used by management. Comparable gross profit
growth, comparable gross margin gain (or growth), comparable
operating expense growth, comparable operating profit growth and
comparable operating margin gain (or growth) should be considered
in addition to, and not as replacements of or superior measures to,
gross profit growth, gross margin gain, operating expense growth,
operating profit growth and operating margin gain reported in
accordance with GAAP.
The reconciliation of these non-GAAP financial measures is as
follows:
Three Months Ended
Year-over-Year
Six Months Ended
Year-over-Year
June 30,
June 30,
Change
June 30,
June 30,
Change
Dollar amounts in thousands
2024
2023
2024
2023
Gross Profit (as reported)
$
619,159
$
572,850
8%
$
1,212,229
$
1,115,821
9%
Gross margin
61.7
%
60.7
%
100 bps
61.6
%
60.5
%
110 bps
Less: comparability adjustments
Change from currency
(3,777
)
—
(3,121
)
—
Comparable gross profit growth
$
622,936
$
572,850
9%
$
1,215,350
$
1,115,821
9%
Comparable gross margin and gross
margin gain (or growth)
61.6
%
60.7
%
90 bps
61.6
%
60.5
%
100 bps
Operating expenses (as
reported)
$
355,358
$
276,706
28%
$
649,470
$
539,278
20%
Less: comparability adjustments
Change from currency
(1,164
)
—
(305
)
—
Ongoing litigation matter
61,500
—
61,500
—
Comparable operating expense
growth
$
295,022
$
276,706
7%
$
588,275
$
539,278
9%
Income from operations (as
reported)
$
263,801
$
296,144
(11)%
$
562,759
$
576,543
(2)%
Operating margin
26.3
%
31.4
%
(510) bps
28.6
%
31.3
%
(270) bps
Less: comparability adjustments
Change from currency
(2,613
)
—
(2,816
)
—
Ongoing litigation matter
(61,500
)
—
(61,500
)
—
Comparable operating profit
growth
$
327,914
$
296,144
11%
$
627,075
$
576,543
9%
Comparable operating margin and
operating margin gain (or growth)
32.4
%
31.4
%
110 bps
31.8
%
31.3
%
50 bps
Amounts presented may not recalculate due
to rounding.
Projected 2024 comparable operating margin expansion outlined in
the 2024 Growth and Financial Performance Outlook section of this
earnings release reflects: (i) projected full year 2024 reported
operating margin is adjusted for impacts of the discrete expense
accrual related to an ongoing litigation matter in the second
quarter of 2024; and (ii) projected full year 2024 reported
operating margin includes an immaterial impact from year-over-year
foreign currency exchange rate changes at noted exchange rates.
These impacts described above reconcile reported gross profit
growth, gross margin gain, operating expense growth, operating
profit growth and operating margin gain (including projected 2024
operating margin expansion) to comparable gross profit growth,
comparable gross margin gain, comparable operating expense growth,
comparable operating profit growth and comparable operating margin
gain for the Company.
Comparable EPS growth - Comparable
EPS growth is a non-GAAP financial measure that represents the
percentage change in earnings per share (diluted) ("EPS") for a
measurement period, as compared to the prior base period, net of
the impact of changes in foreign currency exchange rates from the
prior base period and excluding the tax benefits of share-based
compensation activity under ASU 2016-09, Compensation-Stock
Compensation (Topic 718): Improvements to Employee Share-Based
Payment Accounting, and non-recurring or unusual items (if any).
Management believes comparable EPS growth is a more useful way to
measure the Company’s business performance than EPS growth because
it enables better period-over-period comparisons of the fundamental
financial results by excluding items that vary independent of
performance and provides greater transparency to investors
regarding a key metric used by management. Comparable EPS growth
should be considered in addition to, and not as a replacement of or
a superior measure to, EPS growth reported in accordance with GAAP.
Please refer to the constant currency note above for a summary of
foreign currency exchange rate impacts.
The reconciliation of this non-GAAP financial measure is as
follows:
Three Months Ended
Year-over-Year
Six Months Ended
Year-over-Year
June 30,
June 30,
Growth
June 30,
June 30,
Growth
2024
2023
2024
2023
Earnings per share (diluted)
$
2.44
$
2.67
(9)%
$
5.24
$
5.22
—%
Less: comparability adjustments
Share-based compensation activity
0.00
0.04
0.10
0.10
Ongoing litigation matter
(0.56
)
—
(0.56
)
—
Change from currency
(0.02
)
—
(0.03
)
—
Comparable EPS growth
3.02
2.63
15%
5.73
5.12
12%
Amounts presented may not recalculate due
to rounding.
Projected 2024 comparable EPS growth outlined in the 2024 Growth
and Financial Performance Outlook section of this earnings release
reflects adjustments to projected full year 2024 reported EPS for:
(i) estimated positive share-based compensation activity of ~$0.12;
(ii) a negative $0.56 impact from a discrete expense accrual
related to an ongoing litigation matter in the second quarter of
2024; and (iii) estimated negative year-over-year foreign currency
exchange rate change impact of ~$0.05 at noted exchange rates.
These impacts and those described in the constant currency note
above reconcile reported EPS growth (including projected 2024
reported EPS growth) to comparable EPS growth for the Company.
Free cash flow - Free cash flow is
a non-GAAP financial measure and means, with respect to a
measurement period, the cash generated from operations during that
period, reduced by the Company’s investments in property and
equipment. Management believes free cash flow is a useful measure
because it indicates the cash the operations of the business are
generating after appropriate reinvestment for recurring investments
in property and equipment that are required to operate the
business. Free cash flow should be considered in addition to, and
not as a replacement of or a superior measure to, net cash provided
by operating activities. See the supplementary analysis of results
below for our calculation of free cash flow for the three and six
months ended June 30, 2024 and 2023. To estimate projected 2024
free cash flow, we have deducted projected purchases of property
and equipment (also referred to as capital expenditures) of
approximately $180. Free cash flow conversion, or the net income to
free cash flow ratio, is a non-GAAP financial measure that is
defined as free cash flow, with respect to a measurement period,
divided by net income for the same period. To calculate trailing
twelve-month net income to free cash flow ratio for the twelve
months ended June 30, 2024, we have deducted purchases of property
and equipment of approximately $130 million from net cash provided
from operating activities of approximately $969 million, divided by
net income of approximately $846 million.
Debt to Adjusted EBITDA (Leverage
Ratios) - Adjusted EBITDA, gross debt, and net debt are
non-GAAP financial measures. Adjusted EBITDA is a non-GAAP
financial measure of earnings before interest, taxes, depreciation,
amortization, non-recurring transaction
expenses incurred in connection with acquisitions, share-based
compensation expense, and certain other non-cash losses and
charges. Management believes that reporting Adjusted EBITDA, gross
debt, and net debt in the Debt to Adjusted EBITDA ratios
provides
supplemental analysis to help investors further evaluate the
Company's business performance and available borrowing capacity
under
the Company's credit facility. Adjusted EBITDA, gross debt, and
net debt should be considered in addition to, and not as
replacements of or superior measures to, net income or total debt
reported in accordance with GAAP. For further information on how
Adjusted EBITDA and the Debt to Adjusted EBITDA Ratios are
calculated, see the Company's Annual Report on Form 10-K for the
year ended December 31, 2023 and Quarterly Report on Form 10-Q for
the quarter ended June 30, 2024.
Notes and Definitions
Discrete litigation expense accrual
- During the second quarter of 2024, the Company increased its
previously established $27.5 million accrual related to an ongoing
litigation matter by $61.5 million.
Ongoing litigation matter - The
Company is a defendant in an ongoing litigation matter involving an
alleged breach of contract for underpayment of royalty payments
made from 2004 through 2017 under an expired patent license
agreement. The Company's total accrual of $89.0 million for this
matter includes the discrete $61.5 million litigation expense
accrual recorded in the second quarter of 2024 and represents our
best estimate of the amount of the probable loss. The actual loss
associated with this matter may be higher or lower than the accrued
amount depending on the ultimate outcome of this matter. For
further information, see the Company's Quarterly Report on Form
10-Q for the quarter ended June 30, 2024.
IDEXX Laboratories, Inc. and
Subsidiaries
Condensed Consolidated Statement of
Operations
Amounts in thousands except per share data
(Unaudited)
Three Months Ended
Six Months Ended
June 30,
June 30,
June 30,
June 30,
2024
2023
2024
2023
Revenue:
Revenue
$1,003,578
$943,630
$1,967,673
$1,843,825
Expenses and Income:
Cost of revenue
384,419
370,780
755,444
728,004
Gross profit
619,159
572,850
1,212,229
1,115,821
Sales and marketing
142,665
140,532
292,118
288,336
General and administrative
157,243
89,669
249,267
159,770
Research and development
55,450
46,505
108,085
91,172
Income from operations
263,801
296,144
562,759
576,543
Interest expense, net
(4,745
)
(10,215
)
(8,224
)
(22,926
)
Income before provision for income
taxes
259,056
285,929
554,535
553,617
Provision for income taxes
55,758
61,693
115,658
115,327
Net Income:
Net income attributable to
stockholders
$203,298
$224,236
$438,877
$438,290
Earnings per share: Basic
$2.46
$2.70
$5.30
$5.28
Earnings per share: Diluted
$2.44
$2.67
$5.24
$5.22
Shares outstanding: Basic
82,630
83,086
82,863
83,039
Shares outstanding: Diluted
83,393
83,983
83,684
83,980
IDEXX Laboratories, Inc. and
Subsidiaries
Selected Operating Information
(Unaudited)
Three Months Ended
Six Months Ended
June 30,
June 30,
June 30,
June 30,
2024
2023
2024
2023
Operating Ratios
Gross profit
61.7%
60.7%
61.6%
60.5%
(as a percentage of revenue):
Sales, marketing, general and
administrative expense
29.9%
24.4%
27.5%
24.3%
Research and development expense
5.5%
4.9%
5.5%
4.9%
Income from operations1
26.3%
31.4%
28.6%
31.3%
1Amounts presented may not recalculate due
to rounding.
IDEXX Laboratories, Inc. and
Subsidiaries
Segment Information
Amounts in thousands (Unaudited)
Three Months Ended
June 30, 2024
Percent of Revenue
June 30, 2023
Percent of Revenue
Revenue:
CAG
$922,298
$866,652
Water
46,726
43,029
LPD
30,306
29,911
Other
4,248
4,038
Total
$1,003,578
$943,630
Gross Profit:
CAG
$569,071
61.7
%
$525,709
60.7
%
Water
32,074
68.6
%
30,319
70.5
%
LPD
15,558
51.3
%
16,086
53.8
%
Other
2,456
57.8
%
736
18.2
%
Total
$619,159
61.7
%
$572,850
60.7
%
Income from Operations:
CAG
$241,550
26.2
%
$275,509
31.8
%
Water
20,504
43.9
%
19,820
46.1
%
LPD
1,499
4.9
%
1,951
6.5
%
Other
248
5.8
%
(1,136
)
(28.1
)%
Total
$263,801
26.3
%
$296,144
31.4
%
Six Months Ended
June 30, 2024
Percent of Revenue
June 30, 2023
Percent of Revenue
Revenue:
CAG
$1,811,583
$1,693,931
Water
89,797
81,912
LPD
58,511
59,119
Other
7,782
8,863
Total
$1,967,673
$1,843,825
Gross Profit:
CAG
$1,115,307
61.6
%
$1,024,466
60.5
%
Water
62,571
69.7
%
57,587
70.3
%
LPD
30,792
52.6
%
31,139
52.7
%
Other
3,559
45.7
%
2,629
29.7
%
Total
$1,212,229
61.6
%
$1,115,821
60.5
%
Income from Operations:
CAG
$521,246
28.8
%
$537,259
31.7
%
Water
39,934
44.5
%
36,791
44.9
%
LPD
2,365
4.0
%
3,259
5.5
%
Other
(786
)
(10.1
)%
(766
)
(8.6
)%
Total
$562,759
28.6
%
$576,543
31.3
%
IDEXX Laboratories, Inc. and
Subsidiaries
Revenues and Revenue Growth Analysis by
Product and Service Categories and by Domestic and International
Markets
Amounts in thousands (Unaudited)
Three Months Ended
June 30, 2024
June 30, 2023
Dollar Change
Reported Revenue
Growth1
Percentage Change from
Currency
Percentage Change from
Acquisitions
Organic Revenue
Growth1
Net Revenue
CAG
$922,298
$866,652
$55,646
6.4
%
(0.7
%)
0.4
%
6.7
%
United States
628,684
594,395
34,289
5.8
%
—
0.5
%
5.2
%
International
293,614
272,257
21,357
7.8
%
(2.2
%)
—
10.1
%
Water
46,726
43,029
3,697
8.6
%
(0.9
%)
—
9.5
%
United States
24,461
21,208
3,253
15.3
%
—
—
15.3
%
International
22,265
21,821
444
2.0
%
(1.8
%)
—
3.8
%
LPD
30,306
29,911
395
1.3
%
(1.6
%)
—
2.9
%
United States
5,115
4,422
693
15.7
%
—
—
15.7
%
International
25,191
25,489
(298
)
(1.2
%)
(1.8
%)
—
0.7
%
Other
4,248
4,038
210
5.2
%
—
—
5.2
%
Total Company
$1,003,578
$943,630
$59,948
6.4
%
(0.7
%)
0.3
%
6.7
%
United States
660,146
621,607
38,539
6.2
%
—
0.5
%
5.7
%
International
343,432
322,023
21,409
6.6
%
(2.1
%)
—
8.8
%
Three Months Ended
June 30, 2024
June 30, 2023
Dollar Change
Reported Revenue
Growth1
Percentage Change from
Currency
Percentage Change from
Acquisitions
Organic Revenue
Growth1
Net CAG Revenue
CAG Diagnostics recurring
revenue:
$808,454
$762,476
$45,978
6.0
%
(0.7
%)
—
6.7
%
IDEXX VetLab consumables
325,348
303,735
21,613
7.1
%
(1.0
%)
—
8.1
%
Rapid assay products
103,290
97,340
5,950
6.1
%
(0.4
%)
—
6.5
%
Reference laboratory diagnostic and
consulting services
347,373
330,106
17,267
5.2
%
(0.5
%)
—
5.8
%
CAG Diagnostics services and
accessories
32,443
31,295
1,148
3.7
%
(1.0
%)
—
4.7
%
CAG Diagnostics capital –
instruments
35,292
34,054
1,238
3.6
%
(1.2
%)
—
4.8
%
Veterinary software, services and
diagnostic imaging systems:
78,552
70,122
8,430
12.0
%
(0.1
%)
4.5
%
7.6
%
Recurring revenue
63,117
53,725
9,392
17.5
%
(0.1
%)
5.9
%
11.7
%
Systems and hardware
15,435
16,397
(962
)
(5.9
%)
(0.1
%)
—
(5.8
%)
Net CAG revenue
$922,298
$866,652
$55,646
6.4
%
(0.7
%)
0.4
%
6.7
%
Three Months Ended
June 30, 2024
June 30, 2023
Dollar Change
Reported Revenue
Growth1
Percentage Change from
Currency
Percentage Change from
Acquisitions
Organic Revenue
Growth1
CAG Diagnostics recurring revenue:
$808,454
$762,476
$45,978
6.0
%
(0.7
%)
—
6.7
%
United States
544,466
517,388
27,078
5.2
%
—
—
5.2
%
International
263,988
245,088
18,900
7.7
%
(2.2
%)
—
10.0
%
1See Statements Regarding Non-GAAP
Financial Measures, above. Amounts presented may not recalculate
due to rounding.
IDEXX Laboratories, Inc. and
Subsidiaries
Revenues and Revenue Growth Analysis by
Product and Service Categories and by Domestic and International
Markets
Amounts in thousands (Unaudited)
Six Months Ended
June 30, 2024
June 30, 2023
Dollar Change
Reported Revenue
Growth1
Percentage Change from
Currency
Percentage Change from
Acquisitions
Organic Revenue
Growth1
Net Revenue
CAG
$1,811,583
$1,693,931
$117,652
6.9
%
(0.3
%)
0.3
%
7.0
%
United States
1,230,879
1,158,922
71,957
6.2
%
—
0.5
%
5.7
%
International
580,704
535,009
45,695
8.5
%
(1.1
%)
—
9.7
%
Water
89,797
81,912
7,885
9.6
%
(0.4
%)
—
10.0
%
United States
46,660
41,128
5,532
13.5
%
—
—
13.5
%
International
43,137
40,784
2,353
5.8
%
(0.8
%)
—
6.6
%
LPD
58,511
59,119
(608
)
(1.0
%)
(0.8
%)
—
(0.2
%)
United States
10,279
8,965
1,314
14.7
%
—
—
14.7
%
International
48,232
50,154
(1,922
)
(3.8
%)
(1.0
%)
—
(2.9
%)
Other
7,782
8,863
(1,081
)
(12.2
%)
—
—
(12.2
%)
Total Company
$1,967,673
$1,843,825
$123,848
6.7
%
(0.4
%)
0.3
%
6.8
%
United States
1,291,155
1,212,020
79,135
6.5
%
—
0.4
%
6.1
%
International
676,518
631,805
44,713
7.1
%
(1.1
%)
—
8.1
%
Six Months Ended
June 30, 2024
June 30, 2023
Dollar Change
Reported Revenue
Growth1
Percentage Change from
Currency
Percentage Change from
Acquisitions
Organic Revenue
Growth1
Net CAG Revenue
CAG Diagnostics recurring
revenue:
$1,588,598
$1,489,378
$99,220
6.7
%
(0.3
%)
—
7.0
%
IDEXX VetLab consumables
642,277
594,849
47,428
8.0
%
(0.5
%)
—
8.5
%
Rapid assay products
189,605
179,372
10,233
5.7
%
(0.2
%)
—
5.9
%
Reference laboratory diagnostic and
consulting services
691,711
653,286
38,425
5.9
%
(0.2
%)
—
6.1
%
CAG Diagnostics services and
accessories
65,005
61,871
3,134
5.1
%
(0.7
%)
—
5.7
%
CAG Diagnostics capital –
instruments
69,384
67,198
2,186
3.3
%
(0.8
%)
—
4.0
%
Veterinary software, services and
diagnostic imaging systems:
153,601
137,355
16,246
11.8
%
(0.1
%)
3.9
%
8.0
%
Recurring revenue
122,817
105,432
17,385
16.5
%
(0.1
%)
5.1
%
11.5
%
Systems and hardware
30,784
31,923
(1,139
)
(3.6
%)
(0.1
%)
—
(3.5
%)
Net CAG revenue
$1,811,583
$1,693,931
$117,652
6.9
%
(0.3
%)
0.3
%
7.0
%
Six Months Ended
June 30, 2024
June 30, 2023
Dollar Change
Reported Revenue
Growth1
Percentage Change from
Currency
Percentage Change from
Acquisitions
Organic Revenue
Growth1
CAG Diagnostics recurring revenue:
$1,588,598
$1,489,378
$99,220
6.7
%
(0.3
%)
—
7.0
%
United States
1,067,507
1,008,728
58,779
5.8
%
—
—
5.8
%
International
521,091
480,650
40,441
8.4
%
(1.1
%)
—
9.5
%
1See Statements Regarding Non-GAAP
Financial Measures, above. Amounts presented may not recalculate
due to rounding.
IDEXX Laboratories, Inc. and
Subsidiaries
Condensed Consolidated Balance
Sheet
Amounts in thousands (Unaudited)
June 30, 2024
December 31, 2023
Assets:
Current Assets:
Cash and cash equivalents
$401,590
$453,932
Accounts receivable, net
533,606
457,445
Inventories
379,958
380,282
Other current assets
213,458
203,595
Total current assets
1,528,612
1,495,254
Property and equipment, net
708,178
702,177
Other long-term assets, net
1,178,077
1,062,494
Total assets
$3,414,867
$3,259,925
Liabilities and Stockholders'
Equity:
Current Liabilities:
Accounts payable
$117,468
$110,643
Accrued liabilities
541,124
478,712
Line of credit
250,000
250,000
Current portion of long-term debt
170,112
74,997
Deferred revenue
37,998
37,195
Total current liabilities
1,116,702
951,547
Long-term debt, net of current portion
524,743
622,883
Other long-term liabilities, net
193,169
200,965
Total long-term liabilities
717,912
823,848
Total stockholders' equity
1,580,253
1,484,530
Total liabilities and stockholders'
equity
$3,414,867
$3,259,925
IDEXX Laboratories, Inc. and
Subsidiaries
Selected Balance Sheet Information
(Unaudited)
June 30, 2024
March 31, 2024
December 31,
2023
September 30,
2023
June 30, 2023
Selected Balance Sheet
Information:
Days sales outstanding1
47.3
45.7
46.1
45.6
43.9
Inventory turns2
1.4
1.3
1.3
1.3
1.3
1Days sales outstanding represents the
average of the accounts receivable balances at the beginning and
end of each quarter divided by revenue for that quarter, the result
of which is then multiplied by 91.25 days.
2Inventory turns are calculated as the
ratio of four times our inventory-related cost of product revenue
for the quarter, divided by the average inventory balances at the
beginning and end of each quarter.
IDEXX Laboratories, Inc. and
Subsidiaries
Condensed Consolidated Statement of
Cash Flows
Amounts in thousands (Unaudited)
Six Months Ended
June 30, 2024
June 30, 2023
Operating:
Cash Flows from Operating
Activities:
Net income
$438,877
$438,290
Non-cash adjustments to net income
75,155
76,246
Changes in assets and liabilities
(67,135
)
(130,310
)
Net cash provided by operating
activities
446,897
384,226
Investing:
Cash Flows from Investing
Activities:
Purchases of property and equipment
(63,578
)
(66,981
)
Acquisition of a business
(77,000
)
—
Proceeds from net investment hedges
727
—
Net cash used by investing activities
(139,851
)
(66,981
)
Financing:
Cash Flows from Financing
Activities:
Repayments under credit facility, net
—
(315,000
)
Payments for the acquisition-related
holdbacks
—
(1,780
)
Repurchases of common stock
(370,285
)
—
Proceeds from exercises of stock options
and employee stock purchase plans
26,241
23,086
Shares withheld for statutory tax
withholding payments on restricted stock
(10,268
)
(9,676
)
Other
—
6,256
Net cash used by financing activities
(354,312
)
(297,114
)
Net effect of changes in exchange rates on
cash
(5,076
)
161
Net (decrease) increase in cash and cash
equivalents
(52,342
)
20,292
Cash and cash equivalents, beginning of
period
453,932
112,546
Cash and cash equivalents, end of
period
$401,590
$132,838
IDEXX Laboratories, Inc. and
Subsidiaries
Free Cash Flow
Amounts in thousands (Unaudited)
Three Months Ended
Six Months Ended
June 30, 2024
June 30, 2023
June 30, 2024
June 30, 2023
Free Cash Flow:
Net cash provided by operating
activities
$248,312
$200,314
$446,897
$384,226
Investing cash flows attributable to
purchases of property and equipment
(33,305
)
(27,470
)
(63,578
)
(66,981
)
Free cash flow1
$215,007
$172,844
$383,319
$317,245
1See Statements Regarding Non-GAAP
Financial Measures, above.
IDEXX Laboratories, Inc. and
Subsidiaries
Common Stock Repurchases
Amounts in thousands except per share data
(Unaudited)
Three Months Ended
Six Months Ended
June 30, 2024
June 30, 2023
June 30, 2024
June 30, 2023
Shares repurchased in the open market
415
—
718
—
Shares acquired through employee surrender
for statutory tax withholding
—
—
18
19
Total shares repurchased
415
—
736
19
Cost of shares repurchased in the open
market
$208,169
$—
$375,271
$—
Cost of shares for employee surrenders
79
79
10,268
9,676
Total cost of shares
$208,248
$79
$385,539
$9,676
Average cost per share – open market
repurchases
$501.44
$—
$522.32
$—
Average cost per share – employee
surrenders
$496.95
$469.84
$560.01
$503.35
Average cost per share – total
$501.44
$469.84
$523.26
$503.35
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240805524587/en/
John Ravis, Investor Relations, 1-207-556-8155
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Nov 2024 to Dec 2024
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Dec 2023 to Dec 2024